- |||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca
ATYPICAL HEMOLYTIC UREMIC SYNDROME AND CMV: CAUSE OR CONSEQUENCE? () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_859;
Two months later, she presented peripheral edema and was medicated with furosemide, without clinical response...View Large Image Figure Viewer Download Hi-res image Download (PPT) View Large Image Figure Viewer Download Hi-res image Download (PPT) Results Plasmapheresis and hemodialysis for refractory diseasewere started, eculizumab was initiated after documentation of normal ADAMTS13 levels and valganciclovirwas also started After 16 plasmapheresis sessions, 4 weeks of eculizumab and valganciclovir (prescribed until negative viral load was achieved), steady improvement in renal function and decreasing hemolysis was observed...Furthermore, the genetic panel may not detect all complement associated pathogenic variants. Recent studies suggest that it is safe to stop eculizumab, although more data is required.
- |||||||||| Soliris (eculizumab) / AstraZeneca
A CASE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PRESENTING AS ACUTE KIDNEY INJURY REQUIRING HEMODIALYSIS () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_852;
Conclusions . In this case we highlight the importance of keeping PNH as one of the important differentials in patients with acute kidney injury as it has been well documented that improvement of renal function in PNH by administration of Eculizumab is time dependant with improvement of renal function being less common in CKD stage 3-5 than stages 1-2 of CKD Methods CASE 30-year-old gentleman, was admitted with complaints of fever, dry cough for the past 7 days associated with decreased urine output and passage of cola
- |||||||||| Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
LUPUS NEPHRITIS WITH THROMBOTIC MICROANGIOPATHY RESISTANT TO IMMUNOSUPPRESSION, CASE REPORT () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_805;
Conclusions Patients with TMA and lupus nephritis have a worse renal prognosis. Patients with TMA and lupus nephritis have been treated with plasmapheresis, eculizumab and rituximab in addition to hydroxychloroquine and immunosuppression, based for the most part on case reports, making it necessary to carry out clinical trials to determine the best therapy for these types of patients.
- |||||||||| Soliris (eculizumab) / AstraZeneca
KIDNEY LIMITED COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_799;
A mutation in gene CFB may have predisposed the patient to the outcome. KB was crucial for diagnosis and prompted the treatment with eculizumab with partial recovery without the need for chronic KRT.
- |||||||||| Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
TWO MUTATIONS IN COMPLEMENT FACTOR H GENE CAUSE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_792;
Plasma exchange is depicted with orange arrows, while eculizumab infusion is depicted with green arrows. View Large Image Figure Viewer Download Hi-res image Download (PPT) Conclusions Genetic screening in aHUS is useful in understanding disease pathophysiology and applying proper and timely diagnosis and treatment.
- |||||||||| Soliris (eculizumab) / AstraZeneca, Avastin (bevacizumab) / Roche
ECULIZUMAB FOR BEVACIZUMAB-INDUCED THROMBOTIC MICROANGIOPATHY () - Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_660;
View Large Image Figure Viewer Download Hi-res image Download (PPT) Conclusions Genetic screening in aHUS is useful in understanding disease pathophysiology and applying proper and timely diagnosis and treatment. Methods The clinical and laboratory data of 8-yrs old patient with
- |||||||||| Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Review, Journal: Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. (Pubmed Central) - Mar 25, 2023
Only satralizumab has recruited adolescents in one of the two pivotal clinical trials. Additional clinical trials in pediatric NMOSD are urgently required to evaluate the safety and efficacy of these drugs in this population.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
Pressure Ulcers in the Prone Ventilated Critically Ill Patient With COVID-19 (Walter E. Washington Convention Center, Area B, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_8010;
These case series illustrate and hypothesize that patients with COVID-19 requiring mechanical ventilation in a prone position are at an increased risk for pressure ulcer development from the positioning changes process and the hyperinflammatory state intrinsic to the infection and require frequent skin surveillance. Preventative solutions to decrease shearing forces between the skin and devices should be considered and specific guidelines for prone positioning implemented.
- |||||||||| It Doesn't Have to End That Way: A Case of Acute Fibrinous and Organizing Pneumonia With Spontaneous Resolution (Walter E. Washington Convention Center, Area E, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6302;
His post-transplant course was complicated by skin and gut graft-versus-host-disease treated with ruxolitinib and low-dose prednisone, hemolytic uremic syndrome treated with eculizumab, and relapsing polychondritis discovered on arytenoid biopsy for voice changes...This was treated with 2 weeks of piperacillin-tazobactam but complicated by recurrent fevers, Pseudomonas bacteremia, and enlarging cavity further treated with 3 weeks of meropenem and an extended course of isavuconazole with near-resolution radiographically...In some cases, acute fibrinous and organizing pneumonia can be associated with a more indolent course and may improve spontaneously without steroid treatment, despite histological features typically associated with acute lung injury and a fibroproliferative response to inflammation. Given the favorable response to antibiotic therapy, it is possible that in the case of this patient, fibrinous exudates and features of organizing pneumonia were superimposed upon a microbiologically occult recurrent bacterial infection.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Multiorgan Failure in the Aftermath of Pre-eclampsia With Intracerebral Hemorrhage and HELLP Syndrome (Marriott Marquis Washington, Marquis Ballroom, Salons 9-10 (Level M2)) - Mar 25, 2023 - Abstract #ATS2023ATS_2596;
Despite high-dose pushes of labetalol and hydralazine, her systolic blood pressure remained above 160 mmHg, so a nicardipine infusion was initiated...Limited studies are exploring eculizumab (complement inhibitor) in cases of HELLP-related MAHA...Given her deteriorating neurological status, early intubation and sedation may have allowed for more ideal neuroprotection and stricter blood pressure control. Additionally, this case highlighted the importance of multidisciplinary rounds led by an intensivist, as severe pre-eclampsia often attacks multiple systems and can lead to catastrophic multiorgan failure.
- |||||||||| Soliris (eculizumab) / AstraZeneca
Biomarker, Journal: Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders. (Pubmed Central) - Mar 21, 2023
Recently, eculizumab, a humanized anti-C5 monoclonal antibody, has been clinically applied against neuroimmune diseases such as myasthenia gravis and neuromyelitis optica spectrum disorders (NMOSD)...Complement factor H (CFH), a complement regulatory factor, was decreased in the acute phase as well as in the remission phase of NMOSD, but not in any phases of GBS. Together, these findings suggest that complement biomarkers, such as Ba, sC5b-9 and CFH in peripheral blood, have potential utility in understanding the pathological status of NMOSD.
- |||||||||| Review, Journal: Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature. (Pubmed Central) - Mar 20, 2023
Eculizumab was safely tolerated in all cases, and appeared to be effective in achieving both hematologic and renal recovery in DI-TMA refractory to drug discontinuation and supportive measures, or with severe manifestations associated with significant morbidity or mortality. Our findings suggest that eculizumab may be considered as a potential treatment for severe or refractory DI-TMA that does not improve after initial management, although larger studies are needed.
- |||||||||| Soliris (eculizumab) / AstraZeneca, crovalimab (RG6107) / Roche
Journal: Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors. (Pubmed Central) - Mar 16, 2023
Our findings suggest that eculizumab may be considered as a potential treatment for severe or refractory DI-TMA that does not improve after initial management, although larger studies are needed. Drug-target-drug complexes (DTDCs) are phenomena newly observed in patients who switch from the complement component 5 (C5) inhibitor eculizumab to crovalimab, a novel, anti-C5 antibody in development for paroxysmal nocturnal hemoglobinuria (PNH), because these agents bind to
- |||||||||| Journal: Treatment considerations in myasthenia gravis for the pregnant patient. (Pubmed Central) - Mar 15, 2023
Other monoclonal IgG antibodies such as eculizumab and efgartigimod should be given only when regarded strictly necessary to avoid long-term and severe incapacity...Neonatal myasthenia manifests as a transient weakness caused by the mother's IgG muscle antibodies and affects 10% of babies. MG women should be supported in their wish to have children.
- |||||||||| Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
Journal: Ravulizumab for the treatment of myasthenia gravis. (Pubmed Central) - Mar 14, 2023
P3
MG women should be supported in their wish to have children. Like eculizumab, ravulizumab is an anti-C5 monoclonal antibody, but with an enhanced pharmacokinetic profile, that allows dosing every 8
- |||||||||| Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
High-Efficacy Therapies Reduce Clinical and Radiological Events More Effectively than Traditional Treatments in Neuromyelitis Optica Spectrum Disorder (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4423;
A 15-fold increase in the odds of MRI advancement involving the spinal cord (95% credible interval=[2.34, 287.15]) was observed during treatment with a traditional medication versus with a high-efficacy agent. Conclusions The availability of newer treatments maximizes the opportunity to reduce permanent neurological disability over traditionally used medications in both newly diagnosed and established people with NMOSD.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Soliris (eculizumab) / AstraZeneca, Convalescent Plasma / Stony Brook Medicine
Acute transverse myelitis (ATM) associated with COVID 19 infection and vaccination, A case report and literature review. (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3400;
No cases reported the use of convalescent plasma therapy after infection...One case reported a positive response after treatment with eculizumab, and another with infliximab...Almost all of them reported responding with steroids except one case reported fatal after 58th day after vaccination. Conclusions TM, post-COVID-19 infection, has been described in multiple cases, as well as being a rare complication of COVID-19 vaccination.
- |||||||||| Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1577;
P3
Ravulizumab binds to the same complement component 5 epitope as eculizumab; however, its longer elimination half-life extends the dosing interval (every 8 versus 2 weeks)...Results At baseline, 30/58 ravulizumab-treated patients were receiving monotherapy and 28/58 concomitant immunosuppressive therapy (IST): steroids (n=12), azathioprine (n=7), mycophenolate mofetil (n=6) or other (n=3)...Overall safety profile was consistent with that of ravulizumab across other approved indications. Conclusions The robust effect of ravulizumab on RRR was observed across all prespecified subgroups, including ravulizumab monotherapy, concomitant IST use, age, sex, geographic region, and prior rituximab use.
- |||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Characterization of Early Adopters of Efgartigimod for gMG (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1275;
Regional distribution and primary practice setting did not differ between adopters and non-adopters, nor did reimbursement hassles as a perceived barrier to use (58%, 49%). Conclusions Analysis of efgartigamod early adopters suggests that the prescriber base is driven by specialists with a high volume of gMG patients, with comfort prescribing biologic therapies for gMG.
- |||||||||| Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
Patient-Reported Outcomes and Daily Activity Assessed with a Digital Wearable Device (FITBIT () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2326;
In this pilot study, patients with PNH who were clinically stable on ravulizumab had physical and mental health, fatigue and daily activity similar to the general US population. Higher daily steps and lower resting heart rate were positively correlated with increased quality of life among ravulizumab-treated patients with PNH.
|
